AdAlta Presenting Data on Therapy Candidate AD-114 at Inaugural IPF Summit
Idiopathic Pulmonary Fibrosis, News
AdAlta‘s investigative therapy AD-114, developed for the treatment of idiopathic pulmonary fibrosis (IPF), are in the spotlight at the inaugural IPF Summit Aug. 21-23 in Boston. The IPF Summit brings together leading researchers and pharmaceutical ... Read more